Clinical results.That is the one reason a biotech stock will move.The slump in shares of Gilead Sciences (GILD) may finally be over. The company’s POLARIS Phase 3 trials had positive results. In the study involving 263 genotype 1-6 patients, the drug cured 96% after just 12 weeks.There is more good news.POLARIS-2’s cure rate was 95%.Patients in POLARIS-3 showed a 96% cure rate.Patients in POLARIS-4 showed a 97% cure rate.Investors waiting for the bottom need not wait longer. The stock’s 6.5x P/E makes the stock awfully cheap. The results erase concerns investors have in biotech, whereby the government is scrutinizing high drug prices. Further, the HCV treatment offering over 90% cure rates will widen Gilead’s moat. The safety profile is excellent.